GSK's investigational drug linerixibat has successfully met its primary endpoint in a late-stage study, significantly reducing itch in patients with primary biliary cholangitis. Additionally, GSK's RSV vaccine, Arexvy, has received approval in Japan for use in adults aged 50-59 at increased risk of severe outcomes, expanding its market reach.